Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label Study of ABSK211 to Assess Safety, Tolerability, Efficacy and Pharmacokinetics in Participants With Advanced Solid Tumors With KRAS Alteration

NCT07718165 is registered in ClinicalTrials.gov with Abbisko Therapeutics Co, Ltd as lead sponsor.

NCT NCT07718165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07718165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label Study of ABSK211 to Assess Safety, Tolerability, Efficacy and Pharmacokinetics in Participants With Advanced Solid Tumors With KRAS Alteration
Lead sponsor
Abbisko Therapeutics Co, Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
August 28, 2026
Completion date
June 30, 2030
Enrollment
247 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor (phase i)